AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00646711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depakote Delayed-Release/Depakote Sprinkle
Description: Administered according to the subject's usual regimen.
Study NCT00646711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depakote ER
Description: Dose converted to 8-20% higher than Depakote DR or Depakote Sprinkle.
Study NCT02161198 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Y-75
Description: Y-75 (1 g) and starch (1 g) as a diluting agent and were packed to contain 2 g/package
Study NCT02161198 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Caramel syrup (0.03 g) and starch (1.97 g) were packed identically to the active treatment
Study NCT04255121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% adrenaline lidocaine associated with 4.2% sodium bicarbonate
Description: conversion of epidural analgesia into epidural anesthesia during an emergency caesarean using an alkalinization of adrenaline lidocaine solution
Study NCT04255121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% adrenaline lidocaine
Description: conversion of epidural analgesia into epidural anesthesia during an emergency caesarean using an adrenaline lidocaine solution
Study NCT03713697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pap testing
Description: Un/underscreened women received a home visit by a Community Health Worker and were scheduled an appointment for a Pap testing at the Basic Health Unit
Study NCT03713697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-collection for HPV testing
Description: Un/underscreened women received a home visit by a Community Health Worker and were given a kit to self-collect their own sampling for HPV testing at home
Study NCT03713697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice
Description: Un/underscreened women received a home visit by a Community Health Worker and were given a choice between scheduling an appointment for a Pap testing at the Basic Health Unit or self-collect their own sampling for HPV testing at home
Study NCT04035577 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile self-help intervention
Description: During the trial, participants will use Intellicare apps for up to 8 weeks and will be invited to provide feedback about their experience at two follow-up time points: weeks 4 and 8. All participants will first undergo initial assessments that will include a series of online questionnaires about their mood. Eligible participants will receive up to 8 weeks of access to the IntelliCare system, which consists of apps with a variety of resources, including lessons and tools designed to teach skills for mood management. It is suggested that participants utilize the mobile phone tools every day
Study NCT03382288 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EYESTAR 900
Description: EYESTAR 900 is an optical biometry device used to create a geometrical representation of the eye by means of optical interferometry. The experimental intervention is an optical, non-contact examination with the investigational device EYESTAR 900.
Study NCT03153098 — intervention group
Intervention type: BEHAVIORAL
Intervention: Active Herts
Description: Active Herts is a community physical activity intervention aimed at inactive adults aged 16 and over who have one or more risk factors for CVD and/or a mild to moderate mental health condition. The programme uses the latest evidence-based behaviour change techniques to target physical activity, wellbeing, and key drivers of behaviour from the COM-B model of behaviour change.
Study NCT00264498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: oral tablet
Study NCT00264498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: intravenous injection
Study NCT00264498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: intravenous injection
Study NCT02600598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 43204 Gel, 0.037%
Study NCT04116281 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Rehabilitation after breast cancer surgery
Description: All participants are going to receive physical therapy intervention after breast cancer surgery at least removal drenaige. After that, will be randomized in two groups: Group 1 are going to receive a physical therapy program supervised by a physiotherapist; Group 2 are going to receive some instructions about the same program to perfomr at home without supervision. Both groups are going to receive 3 and 6 months of rehabilitation program.
Study NCT04116281 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation after breast cancer surgery
Description: All participants are going to receive physical therapy intervention after breast cancer surgery at least removal drenaige. After that, will be randomized in two groups: Group 1 are going to receive a physical therapy program supervised by a physiotherapist; Group 2 are going to receive some instructions about the same program to perfomr at home without supervision. Both groups are going to receive 3 and 6 months of rehabilitation program.
Study NCT02148653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multifunctional diet (MFD)
Description: A mixed diet containing multiple functional foods/concepts with the ability to modulate blood lipid levels, glycemia, insulinemia and prothrombotic status.
Study NCT02148653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control diet
Description: A nutritionally well formulated diet that excludes the functional food items present in the MFD.
Study NCT00506272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self blood glucose monitoring and insulin administration
Description: Patients will monitor blood glucose using a hand-held blood glucose monitor, and self-administer insulin
Study NCT00506272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard care
Description: finger-stick blood glucose values to be obtained and all insulin administration to be delivered by nursing staff
Study NCT02972814 — intervention group
Intervention type: DEVICE
Intervention: Laboratory based troponin test
Description: acquisition of blood troponin level by Roche Cobas E 603
Study NCT02972814 — intervention group
Intervention type: DEVICE
Intervention: Point of care based troponin test 1
Description: acquisition of blood troponin level by Radiometer EQT 90 Flex
Study NCT04604964 — intervention group
Intervention type: OTHER
Intervention: Evaluation of anastomotic leakage occurrence
Description: Anastomotic leakage was defined as the communication between the intra and extraluminal compartments due to a defect in the integrity of the intestinal wall originating from the staple line of the neo-rectal reservoir between the colon and rectum
Study NCT02622490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: two test meals with two different macronutrient compositions
Description: Either a high or a low carb meal either as one large or as 5 small meals. ie a crossover trial with one arm
Study NCT02622490 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: two test meals with two different macronutrient compositions
Description: Either a high or a low carb meal either as one large or as 5 small meals. ie a crossover trial with one arm
Study NCT02972814 — intervention group
Intervention type: DEVICE
Intervention: Point of care based troponin test 2
Description: acquisition of blood troponin level by Philips Minicare I-20
Study NCT01041768 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Description: Biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve; Gastric bypass consists of creating a small proximal gastric pouch by division of the upper stomach, with reconstruction of the GI continuity by means of a Roux-en-Y loop
Study NCT01041768 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery
Description: Biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve; Gastric bypass consists of creating a small proximal gastric pouch by division of the upper stomach, with reconstruction of the GI continuity by means of a Roux-en-Y loop
Study NCT03591627 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transesophageal echocardiography
Description: Transesophageal echocardiography will be used to exclude the presence of an LA thrombus before AF/AFI ablation or cardioversion.
Study NCT02019238 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pulmonary Vein Isolation procedure
Description: comparing the efficacy of PVI ablation vs PVI combined with empiric ablation
Study NCT02019238 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Vein Isolation procedure
Description: comparing the efficacy of PVI ablation vs PVI combined with empiric ablation
Study NCT00740870 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Pulmonary Valve replacement
Description: Transcatheter valve implantation into a RVOT conduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs invasive intervention.
Study NCT02370030 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Citrulline malate
Description: Active comparator: 10 g/day citrulline malate during 7 days
Study NCT02370030 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Citrulline malate
Description: Active comparator: 10 g/day citrulline malate during 7 days
Study NCT01068106 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nobori® (Biodegradable polymer limus-eluting stents)
Description: due randomization biodegradable polymer limus-eluting stents will be implanted
Study NCT01068106 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience-V® (Permanent polymer limus-eluting stent)
Description: due randomization permanent polymer limus-eluting stent will be implanted
Study NCT03133078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Step-Down Test (2 min)
Description: The 2-minute single limb lateral-step down test will be used to induce lower extremity muscle fatigue. Participants will be instructed to perform a single limb lateral step-down test on a 31 cm box (12-inches), touching their heel to the floor each time as many times as possible in 2 minutes. The number of lateral step-downs will be recorded.
Study NCT03133078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Side hop test (30 s)
Description: The 30 second side hop test will be used to induce lower extremity muscle fatigue. Participants will be instructed to jump as many times as possible over two parallel strips of tape placed 40 cm apart, but must initiate approximately 30 degrees of knee flexion each jump. The number of successful jumps performed within 30 seconds will be recorded and used for data analysis. An unsuccessful jump will be defined as touching the tape or the area inside the tape. We will record the number of successful trials.
Study NCT00537329 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Anidulafungin
Description: Eligible subjects will be initiated on a single loading dose of 200 mg IV anidulafungin, followed by 100 mg IV anidulafungin once daily for a minimum of 5 days but not more than 42 days.
Study NCT04082377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Recruitment maneuver with tidal volume (RM TV)
Description: The ventilation protocol consisted of volume controlled mechanical ventilation, FiO2 0.4, inspiratory-to-expiratory (I:E) ratio at 1:2, and respiratory rate (RR) set to normocapnia (end-tidal CO2 partial pressure between 35 and 40mmHg, TV 6 mL/kg PBW and 5 cmH2O PEEP.~RMs were conducted under volume controlled ventilation with initial settings of a limit of peak inspiratory pressure at 40cmH2O, TV at 6 mL/kg PBW (PBW = 50.0+0.905\*((height in cm)-152.4) for men, and = 45.5+0.905\*((height in cm)-152.4) for women) Brower, et al. 1999, RR at 7 breaths/min, PEEP at5 cmH2O, and I:E ratio at1:1. The TV was then increased by steps of 4 mL/kg PBW until plateau airway pressure (Pplt) was 40 cmH2O, after which 3 breaths were allowed. Finally, the limit of peak inspiratory pressure, TV, RR, and I:E ratio were reset at values equal to those preceding the RM.
Study NCT04082377 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Recruitment maneuver by PEEP (RM PEEP)
Description: The ventilation protocol consisted of volume controlled mechanical ventilation, FiO2 0.4, in RMs was conducted under pressure controlled ventilation so ventilation technique will be changed, pressure-control mode will be started and inspiratory time is increased to 50% (inspiratory: expiratory ratio will be set to 1:1). Peak airway inspiratory pressure (Ppeak) will be initially set to 20 cmH2O for three breaths, and then PEEP will be increased in steps from 5 to10 cmH2O for five breaths, from 10 to 15 cmH2O for seven breaths, from 15 to 20 cmH2O for ten breaths while Ppeak increased to 40 cmH2O and will be maintained for three more breaths. Following ARM, volume control will be re-established using Vt 6 mL/kg and step-wise reductions in PEEP from 20 to 15 cmH2O for three breaths,and then to 5 cmH2O until the end of recruitment maneuver
Study NCT00953212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: beta blockers
Description: metoprolol 25mg by mouth every 6 hours
Study NCT00953212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amiodarone
Description: amiodarone 600mg by mouth evening before surgery amiodarone 600mg by mouth morning of surgery amiodarone 400mg by mouth every 12 hours for 3 days postoperatively
Study NCT00953212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ascorbic acid
Description: ascorbic acid 2,000mg by mouth evening before surgery ascorbic acid 2,000mg by mouth morning of surgery ascorbic acid 1,000mg by mouth every 12 hours for 5 postoperative days
Study NCT00948610 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remicade
Description: Remicade/ Infliximab Study Material 10mg/kg Total Volume=250cc in saline I.V. route.
Study NCT00948610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remicade
Description: Remicade/ Infliximab Study Material 10mg/kg Total Volume=250cc in saline I.V. route.
Study NCT01299298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mipomersen
Description: 50 mg (cohort A), 100mg (cohort B) or 200mg (cohort C) subcutaneous (SC) single dose of study drug
Study NCT01299298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 50 mg (cohort A), 100mg (cohort B), or 200mg (cohort C) subcutaneous (SC) single dose of study drug
Study NCT04620369 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Instill isotonic nasal saline intranasally
Study NCT04620369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04620369 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04620369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rose Geranium in Sesame Oil Nasal Spray
Description: Instill intranasally
Study NCT01657643 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Study NCT01657643 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03900026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: REPATHA (evolocumab) is a human immunoglobulin G2 (IgG2) monoclonal antibody that has high affinity binding to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9); it will be administered via subcutaneous injection
Study NCT03900026 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo cartridges will contain vehicle only; placebo will be administered via subcutaneous injection.
Study NCT01294410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline, Intravenous, 0mg, Once a week for the first two weeks and every other week thereafter, 7 Weeks
Study NCT01294410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline, Intravenous, 0 mg, Every other week, Up to 757 days
Study NCT01294410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-IP-10 Antibody
Description: Solution for IV administration, Intravenous, 15 mg/kg, Once a week for the first two weeks and every other week thereafter, 7 weeks
Study NCT01294410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-IP-10 Antibody
Description: Solution for IV administration, Intravenous, 25 mg/kg, Once a week for the first two weeks and every other week thereafter, 7 weeks
Study NCT01294410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-IP-10 Antibody
Description: Solution for IV administration, Intravenous, 5 mg/kg, Every other week, Up to 757 days
Study NCT01294410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-IP-10 Antibody
Description: Intravenous, Solution for IV administration, 10 mg/kg, Every other week, Up to 757 days
Study NCT01294410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-IP-10 Antibody
Description: Intravenous, Solution for IV administration, 20 mg/kg, Every other week, Up to 757 days
Study NCT01294410 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Anti-IP-10 Antibody
Description: Intravenous, Solution for IV administration, 15 mg/kg or optimal dose, Every other week. Open
Study NCT03290222 — intervention group
Intervention type: OTHER
Intervention: TRACK questionnaire
Description: TRACK questionnaire consists of five questions, scored 0-20, to be made to caregivers of children with asthma or recurrent respiratory symptoms, regarding respiratory symptoms, nocturnal awakenings and limitation of daily activities in the last four weeks, use of bronchodilators in the last three months and systemic corticosteroids in the last year
Study NCT02468310 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maternal and neonatal emergency protocols
Description: Protocols for management of Maternal and Neonatal emergencies based on the Safe Motherhood protocol adopted by the Ghana Health Service to improve maternal and neonatal health
Study NCT00868764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: granisetron
Description: 3.1 mg/24 hours; transdermal. One patch applied to healthy intact skin on the upper outer arm and worn for 7 days
Study NCT01767662 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: manipulation
Description: home programme
Study NCT01767662 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: No intervention
Description: observation
Study NCT01404533 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Description: 60 mg Ferrous sulfate
Study NCT01404533 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Description: 60 mg ferrous sulfate
Study NCT01404533 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Description: 6 mg ferrous sulfate
Study NCT02849821 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: hypobaric pressure chamber
Description: hypobaric chamber: ascent within 10 minutes, 3 hour exposure to hypoxic conditions simulating an altitude of 4,000 m.a.s.l., afterwards controlled descent under continuous pulsoximetric control
Study NCT02849821 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sigmoidoscopy
Description: To retrieve biopsies from the colon during the course of the study 3 sigmoidoscopies were performed. The first sigmoidoscopy was performed 1 day before the stay in the hypobaric chamber. The second sigmoidoscopy was performed directly after the hypobaric chamber and the third sigmoidoscopy was performed 1 week after the hypobaric chamber. During each sigmoidoscopy 6 biopsies were taken with standard size forceps (2.4 mm). One biopsy was analysed by real-time quantitative polymerase chain reaction (PCR), one biopsy was analysed by Western blotting and another biopsy was analysed for gene gene-expression by in situ hybridisation. Two biopsies were analysed by immunohistochemistry (IHC) and one biopsy was stained with hematoxylin and eosin (H\&E).
Study NCT03354247 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: Participants randomized to the Lifestyle Intervention will receive an intensive, state-of-the-art weight loss intervention based on a Mediterranean diet and physical activity. The intervention will focus on changing both eating and exercise habits with a goal of producing a 7-10% weight loss within the first 6 months and then maintaining this weight loss. Participants will be evaluate using validated questionnaires and adherence scores to assess food intake and physical activity, and will then be closely followed during the intervention period.
Study NCT03246230 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Hepatitis B vaccine (HBV)
Description: Licensed pediatric HBV vaccine will be administered at birth (Day of Life 0) or delayed to Day of Life 7.
Study NCT04183244 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae block
Description: A 5-cm needle prick in the back of the patient 3 cm lateral to mid-line under sterile conditions, with ultrasound guidance.
Study NCT04183244 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infraclavicular subomohyoid (ISO) block
Description: Under complete aseptic precaution, 12 cm needle will be inserted 2cm superior to the clavicle and advanced retroclavicular, with ultrasound guidance.